Role of Embolization in Orthopaedics - Recent Advances

Introduction

Mechanism

• Permanent - using coils, polyvinyl alcohol (PVA) particles, Onyx (ethylene-vinyl alcohol copolymer), or glue (n-BCA)
• Temporary - using Gelfoam (gelatin sponge), which recanalize over weeks

Indications in Orthopaedics

1. Benign Bone Tumors

• Serial arterial embolization is the preferred treatment for sacral GCT where en-bloc excision risks neurological injury
• Embolization can be primary (standalone), preoperative to reduce vascularity, or repeated for local control
• Lackman et al. showed successful control of sacral GCTs by serial embolization (JBJS 2002)
• Also used for GCT in the spine (vertebral body) and inaccessible pelvis
• Campbell's (2026): "Selective arterial embolization is recommended in the treatment of giant cell tumor, aneurysmal bone cyst of spine, and aggressive hemangiomas."

• Embolization reduces vascularity and promotes healing, especially in surgically challenging locations (spine, pelvis, sacrum)
• Can be used as primary treatment or preoperative adjunct to reduce intraoperative bleeding
• Repeat sessions (3-4) may be required for complete regression
• Recent evidence (2023, ScienceDirect) confirms selective embolization as effective primary or adjuvant treatment for ABC

• Embolization reduces pain, prevents pathological fracture, and can be combined with vertebroplasty or surgery
• Must carefully identify the artery of Adamkiewicz (usually at T10-T12 on the left side) - inadvertent embolization causes anterior spinal artery syndrome and paraplegia

2. Malignant Bone Tumors and Metastases

• Reduces intraoperative blood loss in hypervascular tumors before surgical resection
• Most useful for: renal cell carcinoma (RCC) metastases, thyroid metastases, hepatocellular carcinoma metastases (all highly vascular)
• RCC bone metastases in the femur, acetabulum, and spine are the classic indication
• Timing: surgery is optimally performed within 24-72 hours after embolization before collateral re-vascularization occurs
• Acuna et al. (2024, J Surg Oncol): retrospective study confirmed timing between embolization and surgery impacts blood loss in hypervascular bone metastases

• Used for painful bone metastases that are not resectable
• Provides pain relief by tumor devascularization and reduction in size
• Protocol-level RCT ongoing (Zenda et al., BMC Cancer 2023)

• Osteosarcoma and chondrosarcoma: embolization used adjunctively, not as standalone treatment
• Reduces surgical difficulty, especially in pelvic tumors

3. Pelvic Fractures with Hemorrhage

• Life-saving indication - pelvic ring disruptions (type C/Young-Burgess pattern) can cause fatal hemorrhage from the internal iliac artery branches (superior gluteal, obturator, pudendal arteries)
• Protocol: ATLS resuscitation -> pelvic binder/external fixator to reduce pelvic volume -> if hemodynamically unstable despite resuscitation: angiography + embolization (or pelvic packing)
• Time-sensitive: delay >60 minutes from presentation to embolization increases mortality
• Packing vs. embolization debate: Suzuki et al. - these are "complementary, not competitive" approaches (Injury 2009), cited in Rockwood & Green (2025)
• CT-angiography is now routinely used to identify "blush" (active extravasation) before proceeding to embolization

4. Spine Tumors (Vertebral)

• Benign sacral/vertebral tumors (GCT, ABC, hemangioma) treated by serial embolization to avoid major surgery
• Malignant vertebral metastases: preoperative embolization before decompression and stabilization surgery
• Fischer's Mastery of Surgery: "Aneurysmal bone cysts may be treated with arterial embolization, avoiding the morbidity of surgical excision. Benign sacral tumors involving S3 and above may be treated with serial embolization."

5. Post-Traumatic Hemorrhage (Extremity)

• Pseudoaneurysms following orthopaedic trauma or surgery can be treated by coil or glue embolization
• Avoids repeat open surgery in already compromised tissues

Recent Advances (2020-2026)

a) Genicular Artery Embolization (GAE) for Knee Osteoarthritis

• The most exciting recent advance in musculoskeletal embolization
• The synovium of OA knee is hypervascular; embolizing the genicular arteries reduces synovial hyperemia and inflammation, decreasing pain
• Embolic agents: imipenem/cilastatin microspheres (Embosphere), calibrated PVA particles
• Meta-analysis by Epelboym et al. (Cardiovasc Intervent Radiol 2023, PMID 36991094): systematic review confirmed significant pain reduction in knee OA, with durable effects up to 12 months
• Papalexis et al. (Curr Oncol 2024, PMID 39727678): "Its use has expanded globally in treating chronic pain syndromes and osteoarthritis... it offers symptom relief, reduces tumor size, and improves quality of life"
• Also being trialed for shoulder (adhesive capsulitis / frozen shoulder) and hip OA

b) Shoulder Embolization for Adhesive Capsulitis

• Systematic review (Orthopedics Journal 2023): arterial embolization targeting the shoulder synovial vessels shows promising early results for pain and range of motion in frozen shoulder

c) Improved Embolic Agents

• Drug-eluting beads (DEB): loaded with doxorubicin or irinotecan - deliver chemotherapy locally while causing mechanical ischemia (TACE - transarterial chemoembolization concept applied to bone mets)
• Liquid embolics (Onyx/EVOH): better control, can fill complex vascular spaces, used for AVM and GCT
• Calibrated microspheres: allow precise vessel sizing, reduce non-target embolization risk

d) Cone-Beam CT + 3D Roadmap Navigation

• Intraoperative cone-beam CT with 3D roadmap allows real-time, high-resolution guidance during embolization
• Reduces contrast use, improves precision, and reduces complications
• Enables superselective embolization avoiding collateral damage

e) Robotic and AI-Assisted Angiography

• AI-based algorithms for pre-procedure planning, real-time target identification, and radiation dose optimization
• Emerging, still experimental in 2025-26

f) Osteoid Osteoma

• Though primarily treated by radiofrequency ablation (RFA), embolization is a backup in select cases

Embolic Agents: Classification

Complications

1. Post-embolization syndrome - fever, pain, elevated WBC (expected, managed with NSAIDs)
2. Non-target embolization - inadvertent occlusion of normal vessels
3. Anterior spinal artery syndrome - devastating complication from spinal embolization if artery of Adamkiewicz is involved - paraplegia
4. Infection/abscess of embolized tissue
5. Contrast nephropathy - especially in elderly or pre-existing renal disease
6. Recanalization and recurrence - particularly with Gelfoam; requires repeat sessions
7. Skin necrosis - from non-target peripheral embolization

Key Points for Exam

• Embolization = therapeutic vascular occlusion via catheter; not to be confused with pathological embolism
• Classic orthopaedic indications: sacral GCT, ABC of spine, pelvic fracture hemorrhage, hypervascular bone metastases (especially RCC)
• Most exciting recent advance: genicular artery embolization for knee OA pain (strong systematic review evidence, 2023)
• Artery of Adamkiewicz (T10-T12, left side) must be identified before spinal embolization
• Surgery after preoperative embolization should occur within 24-72 hours
• Packing and embolization are complementary, not competing, for pelvic fracture hemorrhage

• Campbell's Operative Orthopaedics, 15th Ed 2026
• Rockwood & Green's Fractures in Adults, 10th Ed 2025
• Papalexis N et al. "How Arterial Embolization Is Transforming Treatment of Oncologic and Degenerative Musculoskeletal Disease." Curr Oncol 2024 [PMID 39727678]
• Epelboym Y et al. "Genicular Artery Embolization for Osteoarthritis Related Knee Pain: Systematic Review and Meta-analysis." Cardiovasc Intervent Radiol 2023 [PMID 36991094]
• Acuna AJ et al. "Effect of timing between preoperative embolization and surgery in hypervascular bone metastases." J Surg Oncol 2024 [PMID 37781952]

Reamer-Irrigator-Aspirator (RIA)

Definition and Concept

Device Components

1. Powered reamer head - cutter heads ranging 10-18 mm in 0.5 mm increments (RIA-2)
2. Drive shaft with locking clip and drive shaft seal
3. Inner irrigation tube - delivers saline to the reamer tip (gravity-fed)
4. Outer aspiration tube - evacuates bone marrow, morselized bone, fat, and debris under vacuum
5. Graft filter canister - 100 cc capacity, mesh-lined to capture bone and marrow while allowing fluid to pass through
6. Vacuum source - creates suction via aspiration tube connected to suction canister

Mechanism of Action

• Fat embolism - elevated intramedullary pressure forces fat globules and debris into emissary veins and the venous system
• Thermal necrosis - heat generated by reaming (without cooling) causes cortical bone necrosis

1. Reams the canal with a rotating fluted cutter
2. Irrigates with saline (reducing heat and intramedullary pressure)
3. Aspirates the mixture of saline, fat, bone marrow, and morselized bone - reducing canal pressure, preventing embolism, and collecting usable graft

Indications

1. Autogenous Bone Graft Harvesting (Primary Use)

• Fracture nonunion - segmental defects averaging 5-8 cm
• Critical-size bone defects after debridement of osteomyelitis
• Spinal fusion (revision cases with pseudarthrosis)
• Ankle and hindfoot arthrodesis
• Tibial plateau and distal femur reconstructions

• Mesenchymal stem cells (MSCs) with pluripotent osteogenic potential
• Osteoinductive growth factors (BMP-2, BMP-7, TGF-beta, IGF-1, VEGF) - in concentrations superior to or comparable to ICBG
• Viable osteoblast precursors
• "Reamings contain pluripotent stem cells with the possibility of dedifferentiation into osteoblasts." - Rockwood & Green (2025)

2. Prevention of Fat Embolism and Thermal Necrosis

• Used instead of conventional reaming before intramedullary nailing in polytrauma patients, chest trauma, and those at risk of fat embolism syndrome
• Continuous irrigation lowers intramedullary temperature and pressure during reaming

3. Treatment of Intramedullary Osteomyelitis

• In chronic osteomyelitis of the femur or tibia, RIA is used to debride the infected medullary canal
• Followed by antibiotic cement rod (antibiotic-loaded PMMA intramedullary rod) placement
• Campbell's (2026) references: "Treatment of intramedullary osteomyelitis of the femur and tibia using the Reamer-Irrigator-Aspirator system and antibiotic cement rods"
• Allows thorough mechanical debridement without open cortical windowing

4. Canal Preparation for Nailing

• Canal enlargement before insertion of a large-diameter nail or prosthesis
• Reduces the "push" effect that forces fat emboli during conventional reaming

Surgical Technique (Campbell's Technique 58.3)

1. Confirm reaming diameter by measuring the diaphyseal isthmus on radiograph
2. Select reamer head no larger than 1.5 mm more than the measured isthmus diameter (prevents cortical perforation)
3. Blood should be available - anticipate potential significant blood loss

1. Position as for standard IM nailing (supine or lateral for femur, supine for tibia)
2. Gain access to canal as for IM nailing
3. Insert guidewire (reaming wire) to the physeal scar; confirm on AP and lateral fluoroscopy
4. Assemble the RIA: attach drive shaft, locking clip, drive shaft seal, drive unit
5. Connect irrigation tube (smaller port) and aspiration tube with graft filter (larger port)
6. Start irrigation and aspiration before insertion to confirm functioning
7. Insert RIA over guidewire; confirm position with image intensification
8. Ream 20-30 mm, then retract 50-80 mm to allow irrigation fluid to fill the space
9. Repeat slow advancement until resistance felt; never ream without irrigation
10. Reamer can be reversed if reaming becomes difficult
11. After removal, stop irrigation and suction; compress graft with plunger; record volume
12. Fluoroscopic check of donor bone for perforation or iatrogenic fracture before closing

• Cadaver studies show RIA does not significantly reduce femoral mechanical properties
• Weight bearing to tolerance is generally permitted in the donor limb

RIA vs. Iliac Crest Bone Graft (ICBG) - Comparison

Complications

• Overall complication rate: 1.7% (95% CI 0.4-3.6%)
• Most common: cortical perforation (34/1834 cases)

Recent Advances (RIA-2 System)

1. Exchangeable cutter heads (10-18 mm, in 0.5 mm increments) - precise sizing for any canal
2. Improved irrigation flow control for better intramedullary pressure management
3. Reduced heat generation
4. Better ergonomic drive unit
5. Intended for adults and adolescents

• RIA aspirate combined with low-intensity pulsed ultrasound (LIPUS) shown to enhance osteogenic differentiation of RIA-derived cells in vitro (Sawauchi et al., 2022, PMID 34785092)
• RIA graft + BMP-2 scaffold combinations for large segmental defects
• RIA as a source of MSCs for tissue engineering - pluripotent cells can be expanded and differentiated for orthobiologic strategies

• Spinal pseudarthrosis revision surgery (Elhessy et al., Cureus 2022)
• Finite element analysis (2026) confirms minimal femoral strength reduction after RIA harvest

Clinical Outcomes

• Nonunion: 70% union at 6 months, 90% at 12 months in segmental defects averaging 5.8 cm (Stafford & Norris)
• Large defects (avg. 6.6 cm): 17/21 healed at 11 months (McCall et al.)
• Osteomyelitis: Favorable results when combined with antibiotic cement rods
• Cost: Less expensive than demineralized bone matrix (DBM) allograft and BMP per 10 cc

Key Points for Exam

1. RIA = reams + irrigates + aspirates simultaneously in a single pass
2. Original purpose: prevent fat embolism and thermal necrosis during IM nailing
3. Now primarily used for: autogenous bone graft harvesting from the femur/tibia
4. Yield: 38-48 cc per femoral harvest; superior growth factor content vs. ICBG
5. Reamer head size: no more than 1.5 mm over the measured isthmus diameter
6. Most common complication: cortical perforation (1.7% overall complication rate - Laubach meta-analysis 2023)
7. Significant blood loss (mean Hb drop 3.74 g/dL) must be anticipated
8. Advantages over ICBG: less donor site pain, fewer infections, no additional incision
9. RIA-2 = current generation; exchangeable cutter heads 10-18 mm
10. Contraindications: thin cortices (osteoporosis), children (open physes), bony deformity of canal, very narrow isthmus

• Campbell's Operative Orthopaedics, 15th Ed 2026 (Technique 58.3, Table 58.5)
• Rockwood & Green's Fractures in Adults, 10th Ed 2025
• Laubach M et al. "Complications associated using the RIA system: systematic review and meta-analysis." Arch Orthop Trauma Surg 2023 [PMID 36114869]
• Oliva F et al. "RIA versus traditional ICBG harvesting: systematic review and meta-analysis." J Orthop Traumatol 2021 [PMID 34851462]
• AO Foundation RIA-2 System Technical Documentation, 2020

Meniscal Repair Techniques, Meniscal Transplantation & Recent Advances

PART 1: MENISCAL REPAIR

Anatomy and Vascular Zones (Basis for Repairability)

Indications for Meniscal Repair

• Tear length 1-4 cm
• Vertical (longitudinal) tear configuration
• Red-red or red-white zone tear
• Patient age < 40 years
• Meniscal root tear (now considered a special indication)
• Concomitant ACL reconstruction extends indications significantly
• Augmentation techniques (fibrin clot, PRP) may extend indications further - Miller's Review of Orthopaedics, 9th Ed

• White-white zone (avascular) tears
• Horizontal cleavage / degenerative tears
• Very small tears (< 1 cm)
• Radial tears (relative; midsubstance radial tears now being repaired)
• Advanced knee OA

Four Techniques of Meniscal Repair

1. Open Repair (Historical)

• Arthrotomy-based; the original technique
• Now rarely used except in combined open procedures (e.g., combined with HTO)
• Allows direct visualization and suture placement
• Sutures: 0-PDS or 2-0 non-absorbable vertical mattress sutures placed through posteromedial or posterolateral capsule

2. Inside-Out Technique (Gold Standard)

• Gold standard for meniscal repair, particularly for posterior horn and body tears
• Long flexible cannulated needles passed from inside the joint, through the tear, and retrieved through a small posteromedial or posterolateral incision
• Suture configuration: vertical mattress (preferred) > horizontal mattress
• Sutures tied over the capsule extraarticularly

1. Arthroscopic setup; posteromedial or posterolateral mini-open incision made
2. Retractor (popliteal retractor) placed to protect neurovascular structures
3. Zone-specific cannula introduced (posterior horn cannula)
4. Long flexible needles (single or double barrel) passed from inside-out through tear
5. Sutures retrieved and tied over capsule
6. Vertical mattress sutures placed 3-4 mm apart

• Medial repairs: protect saphenous nerve (anterior to semitendinosus/gracilis, posterior to inferior sartorius border)
• Lateral repairs: protect common peroneal nerve (posterior to biceps femoris)

3. Outside-In Technique

• Especially useful for anterior horn and body tears; anterior root repairs
• Spinal needles passed from outside through skin, capsule, into joint to exit through the tear
• A suture or wire loop is passed through the needle, retrieved arthroscopically, brought out through an anterior portal, and tied
• Avoids risk to posterior neurovascular structures
• 2026 Review (Pace & Garra, Curr Rev Musculoskelet Med): outside-in remains preferred for anterior horn pathology including meniscal root repairs

4. All-Inside Technique (Most Popular Currently)

• Fully arthroscopic; no accessory incisions needed
• Uses proprietary implant-based devices (FasT-Fix, MaxFire, CrossFix, etc.)
• A flexible shaft deploys a pre-loaded suture anchor/cinch/locking mechanism across both leaves of the tear
• Latest generation devices allow tensioning of the construct (adjustable loop - similar to cortical button concept)
• Best for posterior horn tears, radial tears, and root repairs
• Advantage: no mini-incision, faster, less risk to neurovascular structures
• Disadvantage: device cost; learning curve; risk of chondral injury from implant

Repair Outcomes

• Overall success: 80-90% in published series
• 90% success when repair performed with concurrent ACL reconstruction
• 60% success in repair with intact ACL
• 30% success in repair with ACL-deficient knee
• Results best in: acute peripheral tears, young patients, concurrent ACL reconstruction

Augmentation Techniques

1. Fibrin clot - autologous blood clot prepared from the patient's own venous blood; placed at repair site to deliver growth factors and scaffold
2. PRP (Platelet-Rich Plasma) clot - concentrated platelets with growth factors (TGF-beta, PDGF, IGF-1); injected at repair site
3. Vascular access channels (trephination) - small channels drilled from vascular peripheral zone into avascular tear to allow ingrowth of vessels
4. Synovial rasping - mechanical abrasion of the synovial tissue adjacent to the tear to stimulate bleeding and growth factor release
5. Bone marrow aspirate concentrate (BMAC) - recent advance; MSCs delivered to repair site

Postoperative Rehabilitation

• Avoid knee flexion beyond 90 degrees for 6 weeks
• Weight bearing: controversial; typically partial to full weight bearing in extension with brace
• Return to sport: 4-6 months
• Posterior horn repairs: more cautious ROM restriction

PART 2: MENISCAL ALLOGRAFT TRANSPLANTATION (MAT)

Concept and Background

Indications and Contraindications

• Age < 40 years (up to 50 if highly active with minimal OA)
• Skeletally mature
• Meniscal deficiency (absent or nonfunctioning) with pain in affected compartment
• Failure of conservative management
• Cause of meniscal damage must be mechanical, not degenerative or synovial
• Normal mechanical alignment
• Stable knee (or stabilizable)
• Outerbridge grade I or II articular cartilage changes only

• Knee instability (relative - can address concurrent ACL)
• Varus/valgus malalignment >2-4° (relative - can correct with osteotomy)
• Advanced osteoarthritis (Outerbridge III-IV)
• Inflammatory or synovial disease (will destroy the graft)
• Obesity
• Systemic infection

Graft Procurement and Processing

• Fresh (least common now): viable cells preserved but disease transmission risk, logistics difficulty
• Fresh-frozen (most common): cells lost but structural collagen maintained; low immunogenicity
• Cryopreserved: 10-40% viable cells preserved; however necessity of preserving donor cells questioned (allograft repopulated by host cells)
• Freeze-dried + gamma irradiation: risk of graft shrinkage; irradiation >2.5 Mrad compromises collagen mechanical properties; secondary sterilization with gamma irradiation not currently recommended

1. Cell viability - cryopreservation preserves 10-40% cells; necessity questioned
2. Immunogenicity - deep freezing reduces it; cryopreservation maintains HLA antigens (more immunogenic)
3. Immunologic host response - occurs but clinical significance unknown
4. Disease transmission - freeze-drying + irradiation eliminate viral risk but risk graft shrinkage

Sizing

• Radiographic sizing: tibial plateau AP and ML dimensions on weight-bearing radiographs
• Tibial plateau width and length measured; graft matched within 5 mm
• MRI sizing also used (anterior-posterior and medial-lateral tibial plateau)
• Undersizing leads to instability; oversizing leads to extrusion

Fixation Techniques

Outcomes of MAT

• 13 studies, 619 patients, 632 MATs, mean follow-up 11.1-20 years
• Significant improvements in Lysholm, Tegner, VAS, KOOS
• 10-year MAT survival: 45-100% (most studies ≥73%)
• 15-year survival: 19-87% (highly variable)
• Patient Acceptable Symptom State (PASS): 70-71% for Lysholm, 58-82% for KOOS

PART 3: RECENT ADVANCES

1. Meniscal Scaffold Implantation (MSI)

• CMI (Collagen Meniscus Implant / Menaflex) - collagen-based scaffold from bovine Achilles tendon; for partial medial meniscus deficiency
• Actifit (polyurethane scaffold) - synthetic, porous scaffold; for lateral or medial partial defects; allows tissue ingrowth

• Both MAT and MSI showed significant improvement in clinical scores
• MSI had higher 10-year survival and lower complication rate than MAT
• MAT showed greater pain reduction (VAS improvement)
• MSI: higher IKDC, KOOS improvements

2. Meniscal Root Repair

• Posterior meniscal root tears (equivalent biomechanically to total meniscectomy) are now repaired rather than ignored
• Transtibial pullout repair technique - sutures through root passed through tibial tunnel and tied at cortex
• All-inside root repair with knotless anchors gaining popularity
• Evidence shows root repair prevents rapid OA progression vs meniscectomy

3. Radial Tear Repair

• Previously considered unrepairable; now repaired with specialized techniques
• "Cinch stitch" / horizontal mattress technique
• All-inside devices with ramp configurations
• Evidence supports repair over meniscectomy for radial tears in younger patients

4. Ramp Lesion Repair

• Posterior horn medial meniscus capsular attachment tears (ramp lesions) - common with ACL tears (missed in 9-17% of ACL cases)
• Repaired with all-inside technique using retrograde curved cannulas through intercondylar notch

5. Biologic Augmentation

• PRP injection at repair site - now routinely used; delivers PDGF, TGF-beta, VEGF
• BMAC (Bone Marrow Aspirate Concentrate) - MSCs applied to repair site
• Growth factor-impregnated scaffolds - collagen scaffolds loaded with BMP-7, TGF-beta
• In vitro evidence: low-intensity pulsed ultrasound (LIPUS) enhances meniscal cell osteogenic potential

6. 3D-Printed Personalized Meniscal Scaffolds

• Computed 3D models from patient MRI used to design patient-specific polyurethane or hydrogel scaffolds
• Seeded with autologous chondrocytes or MSCs before implantation
• Experimental phase; promising early results in animal and first-in-human studies

7. Gene Therapy for Meniscal Healing

• Viral vector-mediated delivery of HGF (hepatocyte growth factor), TGF-beta1, or BMP-7 to avascular white-white zone tears
• Aim: convert avascular zone into healing environment
• Preclinical studies only; not yet clinical

8. Adjustable Loop All-Inside Devices

• Latest generation all-inside devices (FiberStitch, MaxFire Meniscal Repair System) with adjustable cinching loops similar to suture button technology
• Allow intraoperative tensioning after placement
• Campbell's (2026): "The latest generation of all-inside devices allows tensioning of the construct"

9. Synthetic Meniscus (NUsurface, Neovasc)

• NUsurface (Active Implants): polycarbonate-urethane total meniscus replacement; does not require fixation (free-floating)
• Approved in Europe; FDA investigational device status in USA
• For patients too old for MAT and not yet needing TKA - the "bridge" population

10. MAT with Concurrent Procedures

• MAT + HTO (High Tibial Osteotomy): for varus knee with medial meniscal deficiency; osteotomy offloads the reconstructed compartment
• MAT + cartilage restoration (OATS, ACI): combined procedures for the young arthritic knee
• MAT + ACL reconstruction: well-established; systematic review (2023) confirms good outcomes
• Note: combined with OCA or ACL reconstruction shows poorer results in some studies (Campbell's)

Summary Table: Repair Techniques

Key Points for Exam

1. Gold standard repair: Inside-out with vertical mattress sutures
2. Vertical > horizontal mattress sutures in biomechanical testing (Desai 2025)
3. Repair zone: Red-red and red-white; never white-white
4. Best repair outcomes: Young patient + peripheral tear + concurrent ACL reconstruction = 90% success
5. MAT candidate: Age <40, mechanical deficiency, Outerbridge ≤II, aligned, stable knee
6. MAT fixation: bone bridge (medial) vs bone plugs (lateral) vs soft tissue
7. MAT 10-year survival: 45-100%; most studies report ≥73% (Kodra 2026)
8. MSI has higher 10-year survival and fewer complications than MAT (Dong 2024)
9. Meniscal extrusion present in most MAT patients; reduces chondroprotection at >10 years
10. Augmentation: fibrin clot, PRP, trephination, synovial rasping extend repair indications

• Campbell's Operative Orthopaedics, 15th Ed 2026 (Chapter 50, Box 50.1)
• Miller's Review of Orthopaedics, 9th Ed (Chapter 4, Fig 4.12)
• Desai SS et al. "Neither AI, IO, nor OI Repair demonstrates superior biomechanical properties." Arthroscopy 2025 [PMID 38880182]
• Kodra JD et al. "Long-term Outcomes and Survivorship of MAT: minimum 10-year follow-up." Am J Sports Med 2026 [PMID 41549414]
• Dong J et al. "MAT vs MSI outcome comparison: systematic review." Int J Surg 2024 [PMID 38742839]
• Leite CBG et al. "Medial MAT: >5-year systematic review." Arthroscopy 2023 [PMID 36543661]
• Pace JL & Garra S. "Outside-In Meniscal Repair." Curr Rev Musculoskelet Med 2026 [PMID 41709039]

Autologous Chondrocyte Implantation (ACI)

Introduction and Historical Background

Biology of Articular Cartilage and the Need for ACI

• Avascular, aneural, alymphatic - extremely limited intrinsic healing
• Composed of chondrocytes in a type II collagen / proteoglycan matrix
• Full-thickness defects (reaching subchondral bone) do not heal spontaneously with hyaline cartilage

Indications

• Age: Typically 15-50 years (skeletally mature, not yet a candidate for arthroplasty)
• Defect size: Single defects >2 cm² (small defects managed with microfracture/OATS)
• For larger defects: up to 10 cm² (MACI)
• Focal, symptomatic full-thickness chondral defects (Outerbridge grade III-IV)
• Femoral condyle (medial or lateral) - most common; also trochlea, patella, tibial plateau
• Failed prior cartilage repair (salvage)
• Osteochondritis dissecans (OCD)
• Meniscal deficiency, malalignment, and ligamentous instability must be corrected before or at the time of ACI

Contraindications

• Advanced osteoarthritis (diffuse, not focal)
• Inflammatory joint disease (RA, crystalline arthropathy) - will destroy implanted cells
• Uncorrected malalignment
• Uncorrected ligamentous instability
• Significant subchondral bone loss without bone grafting
• Severe obesity
• Skeletal immaturity (relative)
• Inability to comply with postoperative rehabilitation

Three Generations of ACI

Generation 1: Classic ACI (Periosteal Patch)

1. Arthroscopy to confirm defect suitability
2. Harvest 200-300 mg cartilage biopsy from a non-weight-bearing area (intercondylar notch, superomedial femoral condyle)
3. Specimen sent to laboratory for chondrocyte isolation and expansion

• Enzymatic digestion of cartilage (collagenase) releases chondrocytes
• Monolayer culture expansion for 3-6 weeks until 12-48 million cells obtained (6-8 population doublings)
• Cell viability confirmed before implantation

1. Mini-arthrotomy (medial or lateral parapatellar)
2. Defect debridement to stable cartilage margins; vertical walls created; subchondral bone intact
3. Periosteal graft harvested from medial tibial metaphysis
4. Periosteal patch sutured (watertight) over the defect with 2-0 Vicryl sutures, cambium layer facing down
5. Small gap left; cell suspension injected under the patch via cannula
6. Gap sealed with fibrin glue

• Periosteal patch hypertrophy (up to 25-36% of cases) requiring arthroscopic shaving
• Periosteal graft delamination and calcification
• Cell suspension leakage
• Requires two procedures + arthrotomy
• Technically demanding, longer surgery

Generation 2: ACI with Collagen Membrane (ACI-C)

• Porcine type I/III collagen membrane (Bio-Gide, Chondro-Gide) replaces periosteal patch
• Reduced hypertrophy rate significantly
• Otherwise same technique as Gen 1
• Cells injected under membrane; fibrin glue seal
• ChondroCelect (TiGenix, Belgium): first EU-approved ACI cell product with characterized biomarkers of stable cartilage-forming potential (EMA registered under Advanced Therapy Medicinal Product regulation)
• RCT: ChondroCelect produced structurally superior repair tissue at 12 months and superior clinical outcome at 3 years vs microfracture; non-inferior at 5 years overall, but superior in patients with lesions <3 years old - Firestein & Kelley's Rheumatology (2022)

Generation 3: MACI - Matrix-Induced ACI (Current Standard)

• Mini-arthrotomy or arthroscopic (newer approach)
• Defect prepared: debridement to stable walls, subchondral bone preserved
• Defect measured, membrane trimmed to exact defect size/shape
• MACI membrane (cells seeded on one side) placed cell-side down into defect
• Fixed with fibrin glue only - no sutures needed
• Membrane conforms to irregular defect shapes
• Campbell's (2026): "Although prior generations required a periosteal graft sutured over the defect, the current iteration requires fixation with fibrin glue only."

• No periosteal harvest (no donor site morbidity)
• No graft hypertrophy
• Improved cell distribution (3D scaffold)
• Fibrin glue only - simpler, faster
• Can be applied arthroscopically
• Reduced cell leakage
• 3D environment prevents chondrocyte dedifferentiation

Cartilage Treatment Algorithm by Defect Size

Postoperative Rehabilitation

• Optimal outcome reached at 18-24 months
• Lack of low-load activities after surgery (in both ACI and microfracture groups) adversely affects functional outcomes - Campbell's (2026)

Outcomes

Long-Term Results

• 188 chondral defects, mean age 37, mean BMI 26.2
• Significant, durable improvements in all PRO measures at 10-17 years
• MRI: satisfactory defect fill and intact graft in majority
• All-cause reoperation rate: 9.0%
• Progression to TKA: 7.4% at 10-17 years
• "These data support the use of MACI as a long-term treatment of focal cartilage defects."

• 235 patients; defects 2.2-15.1 cm² (ACI) and 2.0-7.6 cm² (MACI)
• Stable improvements up to 11 years (ACI) and 15 years (MACI)
• Failure rate ~10% at 11 years
• Both procedures delayed progression to arthroplasty

• 47 studies, 1,993 patients, mean follow-up 57 months
• All four procedures showed significant improvements in Lysholm, IKDC, Tegner, and VAS scores
• No significant differences between ACI, MACI, OAT, and OCA
• OAT surpassed PASS threshold for IKDC; all surpassed Lysholm and Tegner PASS
• Conclusion: Technique selection should be individualized based on patient and defect characteristics

• 965 patients; OR = 8.75 (95% CI 7.1-10.7) for significant improvement in osteochondral defects

Positive Predictors of Good Outcome

1. Young patient age
2. Femoral condyle location (vs patella/trochlea)
3. Early intervention (<3 years after becoming symptomatic)
4. Good quality harvested chondrocytes
5. Well-trained surgeon
6. Strict rehabilitation adherence
7. No radiographic signs of OA

Complications

ACI vs Microfracture - Key Comparison

Recent Advances

1. Arthroscopic MACI

• MACI now deliverable fully arthroscopically (no arthrotomy)
• Reduced soft tissue trauma, faster recovery, better cosmesis
• Statistically better outcomes vs microfracture at 2 years in arthroscopic delivery study - Firestein & Kelley (2022)

2. High-Density ACI (HD-ACI)

• Guillén-García et al. (Bioengineering 2023, PMID 37760185): increased cell density implantation improves matrix production and mechanical properties
• May reduce need for extended culture periods

3. Nasal Chondrocytes

• Chondrocytes from nasal septum have known stable chondrogenic capacity (do not dedifferentiate with age/mechanical unloading as readily as articular chondrocytes)
• Safe and effective in 10-patient pilot study for knee defects - Firestein & Kelley
• Also trialled in two patients with advanced OA (KL grade 3-4) with promising early results
• Large-scale controlled trials needed

4. MSC-Based Approaches (Cell-Free or Alternative Cell Sources)

• MSCs from bone marrow, adipose tissue, synovial membrane can differentiate into chondrocytes
• Bone marrow MSCs = at least as effective as chondrocytes for symptomatic improvement
• Adipose-derived stem cells (ADSCs): abundant source, minimal donor site morbidity
• Synovial MSCs: highest chondrogenic potential among MSC sources
• Challenge: MSCs produce transient fibrocartilage rather than stable hyaline cartilage without scaffold guidance - Rheumatology 2-Vol Set (2022)

5. Hydrogel-Enhanced ACI

• Hydrogels (alginate, fibrin, hyaluronic acid, PEG-based) as 3D injectable carriers
• Provide structural support and prevent chondrocyte dedifferentiation
• Can be injected minimally invasively - no arthrotomy needed
• Ahmadpoor et al. (Bioengineering 2024, PMID 39593824): updated preclinical review of hydrogel-enhanced ACI showing improved cell viability and matrix production

6. 3D Bioprinting / Bioengineered Constructs

• Patient-specific 3D-printed collagen/bioink scaffolds seeded with autologous chondrocytes
• Precise anatomical match to defect geometry
• Combined with growth factors (TGF-beta3, BMP-6, IGF-1)

7. Gene Therapy Augmentation

• CRISPR/Cas9 gene editing used to modify harvested chondrocytes to upregulate type II collagen synthesis, overexpress SOX9 (master chondrogenic transcription factor), or knock out catabolic factors (IL-1, MMP-13)
• Focsa et al. (Medicina 2024, PMID 39859006): CRISPR combined with ACI shows targeted cellular modification potential
• Still experimental/preclinical phase

8. Biophysical Stimulation

• LIPUS (Low-Intensity Pulsed Ultrasound): enhances chondrogenic differentiation and ECM production
• Electromagnetic fields (EMFs): promote chondrogenesis; combined with ACI in preclinical models
• Both being trialled as intraoperative or postoperative adjuncts to accelerate graft maturation

9. Non-Autologous / Off-The-Shelf Alternatives

• CARTIMAX / Cartiform: allogeneic chondrocytes/acellular scaffolds (FDA approved)
• Agili-C (aragonite + hyaluronan scaffold, Cartiheal): FDA approved 2022; shown to outperform microfracture/debridement in mild-moderate OA in RCT; good MRI filling - Campbell's (2026)
• Juvenile particulate cartilage (IMPACT/DeNovo NT): juvenile allogeneic chondrocytes with higher metabolic activity than adult cells; single-stage procedure
• Cryopreserved viable osteochondral allografts: small cohort studies show good results, low failure rate

Key Points for Exam

1. ACI = two-stage procedure: biopsy → lab expansion → reimplantation
2. Pioneer: Brittberg et al., 1994; first commercial product: Carticel, 1997
3. Defect size: suitable for >2 cm² single focal full-thickness defects
4. Three generations: Gen 1 (periosteal patch) → Gen 2 (collagen membrane) → Gen 3/MACI (cell-seeded matrix, fibrin glue only)
5. MACI = current gold standard; no periosteal harvest, no sutures, fibrin glue fixation
6. Regenerates hyaline-like (type II collagen) tissue vs fibrocartilage from microfracture
7. MACI at 10+ years: 9% reoperation, 7.4% TKA progression, durable PRO improvements (Wang 2024)
8. All four procedures (ACI, MACI, OAT, OCA) show comparable outcomes (Nassar 2025)
9. Optimal outcome at 18-24 months; return to sport ~12-18 months
10. Must correct: malalignment, ligament instability, meniscal deficiency before/during ACI
11. Positive predictors: young age, femoral condyle, early intervention (<3 years), good chondrocyte quality
12. Most exciting recent advances: arthroscopic MACI, nasal chondrocytes, hydrogel carriers, 3D bioprinting, CRISPR-modified chondrocytes, Agili-C (FDA 2022)

• Campbell's Operative Orthopaedics, 15th Ed 2026 (Chapter 50, MACI section)
• Firestein & Kelley's Textbook of Rheumatology (2022)
• Rheumatology 2-Vol Set, Elsevier (2022)
• Wang AS et al. "Minimum 10-Year Outcomes of MACI." Am J Sports Med 2024 [PMID 38312085]
• Nassar JE et al. "ACI, MACI, OAT and OCA improve knee function: meta-analysis." KSSTA 2025 [PMID 39497425]
• Colombini A et al. "ACI provides good long-term results in knee OA." KSSTA 2023 [PMID 35716187]
• Almohaileb FI & Rasheed Z. "Clinical Applicability of ACI: meta-analysis." Curr Rheumatol Rev 2024 [PMID 37957845]
• Focsa MA et al. "Emerging Strategies in Cartilage Repair." Medicina 2024 [PMID 39859006]